News, Forecasts and Stock Analysis for 26 December 2025
Panacea Biotec Limited (NSE: PANACEABIO, BSE: 531349) became one of India’s standout movers on Friday, December 26, 2025, after the company disclosed a meaningful upgrade to its UNICEF vaccine supply award—an update that immediately lit up the stock tape even as the broader market drifted in thin year-end trade. [1]
By midday, Panacea Biotec’s share price was sharply higher and trading at levels not seen in weeks, supported by heavy volumes and a surge in traded value. The catalyst wasn’t vague “sentiment” or rumor—it was a concrete, exchange-filed change in contracted order values for a WHO pre-qualified pentavalent vaccine (Easyfive‑TT®), which materially improves revenue visibility for calendar years 2026 and 2027.
